wearables/drug delivery · experimental
Reference snapshot
This snapshot describes the state of the editorial record, not a diagnosis or a recommendation to intervene.
Claim ledger
These are declared editorial claim-to-source mappings. A mapping does not establish independent verification of the claim or its support. Citation controls open the corresponding source record.
Signal
A small human pilot demonstrates feasibility of wearable interstitial-fluid drug sensing for a defined drug and patch design.
Boundary
Calibration, sensor degradation, tissue lag, drug specificity, reference testing, and clinical decision impact remain essential translation gates.
Not established
A prototype patch does not replace validated therapeutic-drug monitoring or authorize self-directed medication titration.
Mechanism map (working model)
A simplified causal map for orientation; it is not a diagnosis or a deterministic prediction.
Input or intervention
Drug concentration estimated from dermal interstitial fluid or another wearable-accessible compartment
Biological pathway
Sensor chemistry, tissue transport, calibration, pharmacokinetics, algorithmic estimation, and clinician decision support
Measurable signal
Paired-reference agreement, usable window, drift, lag, therapeutic-window accuracy, and dosing safety
Boundary
Continuous measurement is not automatically accurate, clinically actionable, or safe for autonomous dosing.
Research appraisal checklist
Evidence to prioritize
Mechanistic work plus independent replication, well-described human feasibility or clinical studies, regulatory context, and long-term safety evidence. Regulatory status, contraindications, specialist oversight, and a credible stop or adverse-event pathway are part of the evidence—not optional extras.
Outcome anchor
Treat mechanism, model performance, and surrogate movement as intermediate signals until they connect to durable human function or health outcomes.
Main uncertainty
The main uncertainty is translation: whether the intervention can be delivered safely, reproducibly, and usefully in the intended human population.
What would change the conclusion
Upgrade confidence only when independent studies reproduce the result and make harms, adherence, and durability visible.
Minimum diligence questions
- Are the intervention, dose or exposure, comparator, population, and measurement conditions clearly defined?
- Do the outcomes matter outside the experiment, and are missing data, adverse events, and conflicts visible?
- Can the result be reproduced independently, and does it justify the level of risk being discussed?
Application and translation pathway
Current application boundary
Early human biosensing research for selected drugs; routine therapeutic-drug monitoring and automated dosing are not established.
Research and applied uses
- Continuous pharmacokinetic measurement
- Narrow-therapeutic-window medication research
- Closed-loop care and adherence support
A staged map for separating an interesting mechanism from a reproducible, useful, and responsibly deployable application.
Drug
Select a defined molecule, compartment, therapeutic window, and reference method.
Sensor
Validate calibration, selectivity, tissue lag, degradation, wear time, and skin tolerance.
Decision
Show that the signal improves a clinician-led decision compared with standard monitoring.
Govern
Keep dosing under qualified oversight with human override, privacy, and confirmatory testing.
Research and clinical readout
Research status
Wearable electrochemical and aptamer systems are beginning to measure selected drugs in dermal interstitial fluid, but early human studies remain small, drug-specific, and constrained by calibration and sensor degradation.
Signal confidence
Grade D (Early feasibility for defined molecules and devices; low for routine therapeutic-drug monitoring, automated dosing, or broad personalized pharmacology.)
Key question
Can a wearable concentration estimate be accurate, stable, timely, and clinically actionable enough to improve medication safety over validated laboratory monitoring?
Clinical perspective
Medication decisions require validated pharmacokinetics, a known therapeutic window, clinical context, and prescriber or pharmacist review; a prototype signal cannot authorize self-titration.
Clinical uncertainty
Which drugs, compartments, calibration approaches, and clinical workflows are most likely to benefit from continuous sensing.
Community patterns
People imagine patches that reveal stimulant, antibiotic, hormone, or supplement exposure and enable truly personalized dosing.
Common community failure mode
Treating continuous measurement as automatically accurate or assuming a high-frequency signal is better than a validated clinical test.
Where this is heading
Multi-analyte sensing, longer stable windows, paired reference studies, pharmacokinetic modeling, and clinician-facing decision trials could support narrow closed-loop applications.
What to track next
Wearable drug-sensing systems aim to estimate medication concentrations from interstitial fluid or other accessible signals and could eventually support more responsive dosing, but human validation is still early and drug-specific.
Protocol and safety scaffold
Risk gate: A wearable drug sensor is an investigational measurement unless the specific device, drug, and workflow are validated; never self-adjust medication from a prototype.
Baseline first
- Record drug, dose, therapeutic window, reference laboratory method, compartment, calibration, sensor wear time, and clinical decision owner.
- Define lag, missingness, sensor degradation, privacy, and the threshold for confirmatory testing.
Implementation pattern
- Use paired reference samples and clinician or pharmacist review during validation.
- Treat readings as supportive research data until accuracy, stability, and decision benefit are demonstrated.
Monitor
- Agreement, drift, tissue lag, skin response, medication effect, symptoms, adherence burden, and false alarms.
- Whether the sensor changes a safe and beneficial decision compared with standard monitoring.
Pause or stop rules
- Stop self-directed dosing for implausible readings, device failure, severe symptoms, or sensor skin injury; confirm with a qualified clinical pathway.
- Pause use if data are being used for automated dosing without validated safeguards and human override.
Clinician gate
Prescriber, pharmacist, clinical laboratory, and device-specialist input is required for any medication or therapeutic-drug-monitoring decision.
Glossary connections
Controversies to monitor
Controversies
- Patient autonomy versus unsafe automated dosing.
- Data ownership and the privacy of medication adherence or illicit-drug signals.
- Sensor-market incentives that blur research feasibility and clinical readiness.
Core reference classes
Research classes
- 2026 pilot clinical trial of a wearable aptamer drug patch
- Therapeutic-drug monitoring and interstitial-fluid validation literature
Evidence timeline
Linked records are ordered by publication year. A newer record is not automatically stronger; design, population, and endpoint still determine weight.
Wearable Aptamer Patch for Continuous Drug Concentration
Nature Biotechnology / PubMed - Pilot phase clinical trial
A pilot study in six healthy participants tested a wearable electrochemical aptamer patch that measured vancomycin in dermal interstitial fluid at five-minute resolution; sensor degradation limited the most interpretable data window.
View source recordTopic assessment
These questions test evidence interpretation and safety boundaries, not personal medical decisions.
1. What is the most defensible first question when evaluating Wearable Drug Sensing and Closed-Loop Pharmacology?
Show answer and explanation
What outcome, evidence, and risk boundary are defined?
A clear outcome, evidence design, and risk boundary keep an encyclopedia claim from becoming an unsafe recommendation.
2. What would make a claim about Wearable Drug Sensing and Closed-Loop Pharmacology more trustworthy?
Show answer and explanation
Replication with appropriate controls, context, and meaningful outcomes
Reproducibility and patient-important outcomes matter more than novelty, complexity, or an isolated signal.
Editorial update history
This log records what changed in the encyclopedia record and why the update matters for interpretation.
A-Z topic scaffolding, safety framing, learning paths, and linked evidence architecture established for the living encyclopedia.
Added current records spanning real-world digital cohorts, multi-omics, serum proteomics, sweat biosensing, peptides, aging clocks, kinase signaling, endocrine research, personalized nutrition, microbiome response, neurotechnology, and caloric restriction.
Related record update: Wearable Aptamer Patch for Continuous Drug Concentration
Added hyperbaric oxygen, wearable drug sensing, and menopause cognition and sleep coverage, connecting clinical indications to device safety, individualized treatment, symptom outcomes, and boundaries around anti-aging or enhancement claims.
Related record update: Wearable Aptamer Patch for Continuous Drug Concentration
Linked evidence records
Wearable Aptamer Patch for Continuous Drug Concentration
Nature Biotechnology / PubMed • Pilot phase clinical trial • Published: 2026 • Checked: Aug 17, 2026
A pilot study in six healthy participants tested a wearable electrochemical aptamer patch that measured vancomycin in dermal interstitial fluid at five-minute resolution; sensor degradation limited the most interpretable data window.
How to interpret this record
What it supports
A small human pilot demonstrates feasibility of wearable interstitial-fluid drug sensing at high temporal resolution for a defined drug and patch design.
Major limitations
Only six healthy participants were studied, sensor degradation narrowed the usable window, and performance was not established for routine therapeutic dosing decisions.
What it does not establish
A prototype patch does not replace validated blood testing, therapeutic-drug monitoring, or clinician-directed medication management.